Leukemia L1210

11/01/2005 - "To reach these goals, we studied the expression of alpha-Man-rich membrane GPs in murine leukemia L1210 cells inoculated into abdominal cavities of mice which were then subjected to the action of apoptosis inducer doxorubicin. "
08/01/2005 - "The present conjugate exhibited cytotoxicity lower than that of free doxorubicin (IC50=0.10 microM) but a reasonably higher in vitro cytotoxicity (IC50=1.1 microM) against the leukemia L1210 cell line probably due to its enzymatically controlled release."
02/20/1992 - "In vivo, the drug-resistant L1210 leukemia was completely unresponsive to i.v. monotherapy with adriamycin at its maximum tolerated dose (MTD). "
03/01/1991 - "Time course of MDR gene amplification during in vivo selection for doxorubicin-resistance and during reversal in murine leukemia L 1210."
09/01/1984 - "It was also active against intravenously implanted L1210 leukemia, in contrast to doxorubicin, though this is considered to have a similar mode of action. "

03/01/1973 - "A dose-response study of resistance of leukemia L1210 to cyclophosphamide."
10/01/1991 - "The tetrakis(chloroethyl)phosphorodiamidates were highly potent in vitro against both cyclophosphamide-sensitive and -resistant L1210 and P388 cell lines, and one of these analogues had significant antitumor activity against L1210 leukemia in vivo. "
03/01/1987 - "Mechanisms of immunological response induced in CD2F1 mice by administration of semisyngeneic L 1210 leukemia cells treated with cyclophosphamide."
01/01/1987 - "administration of L 1210 leukemia cells treated with cyclophosphamide (L 1210-CY cells) were examined. "
01/01/1987 - "Cellular composition of spleen and peritoneal exudate in mice after injection of cyclophosphamide-treated L 1210 leukemia cells."

12/01/1984 - "These data indicate that 5-aza-dCyd is more effective than ara-C against the ic L1210 leukemia."
08/01/1983 - "However, they were found to be marginally effective against i.p.-implanted ara-C-resistant L1210 leukemia in mice. "
05/01/1969 - "Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to 1-beta-D-arabinofuranosylcytosine (Cytarabine)."
01/01/2011 - "Using an optimized dose-schedule we showed that this combination could cure some mice bearing L1210 leukemia, even in the presence of a subpopulation of drug-resistant (L1210/ARA-C) leukemic cells lacking DCK. "
05/01/1993 - "In the experiments included in this report, murine leukemia (L1210) cells were exposed to various concentrations of Ara-C for 1, 6 or 24 hours, and their responses quantified. "

01/01/1959 - "Studies of 5-fluorouracil in the treatment of L1210 leukemia in mice."
11/01/2005 - "All of the conjugates displayed dose-dependent cytotoxicity against the leukemia L1210 cell line and exhibited more pronounced cytotoxic effects than did 5-FU."
06/01/1997 - "The results suggest the possibility that the synergism of AS 15557 in combination with 5-FU may be dependent on the relationship between the indirect immunological function of AS 15557 and the direct cytotoxic action of 5-FU on L1210 leukemia cells."
06/01/1997 - "The antileukemic action of AS 15557, alone or in combination with 5-FU, against L1210 leukemia was superior to that of a streptococcal preparation (OK-432) and was almost the same as of bacillus Calmette-Guérin with or without 5-FU. "
06/01/1997 - "Synergistic effects of Actinobacillus suis cells in combination with 5-fluorouracil on mice bearing murine L1210 leukemia cells."

08/01/2003 - "Mice inoculated with L1210 leukemia cells or with B16F10 melanoma cells were treated with 7 daily injections of low-dose DAC (0.2 mg/kg) and/or 7 daily doses of IL-12 (100 ng/dose). "
12/01/1999 - "In our recent study we described a significant antileukemic efficacy of a combination therapy with interleukin-12 (IL-12) and doxorubicin (DOX) in the L1210 leukemia model. "
04/01/2001 - "In this study we investigated the efficacy of a combination of IL-12 and 5-FU, a chemotherapeutic exerting several immunomodulatory effects, in murine L1210 leukemia. "
01/01/2000 - "In this study we investigated the efficacy of a combination of IL-12 and mitoxantrone in murine L1210 leukemia. "
12/01/1999 - "We described previously lack of the potentiation of antitumor effects in combination treatment with IL-12 and paclitaxel in a murine leukemia L1210 model. "

02/01/1980 - "A comparative cytogenetic study of melphalan-sensitive and -resistant murine L1210 leukemia cells."
01/01/1990 - "However, both P388 and L1210 leukemia sublines resistant to melphalan (L-PAM) were cross-resistant to PZDH, suggesting that patients previously treated with L-PAM might have less likelihood of response to PZDH than those who had had no opportunity to develop L-PAM resistance. "
04/01/1989 - "Compounds 3 and 4 are active on melphalan-resistant L1210 leukemia in mice."
05/01/1987 - "These results indicate that the enzyme is present in both sensitive and resistant murine L1210 leukemia cells but that the cellular content of gamma-GT is elevated two-to threefold in L-PAM resistant cells as compared to their sensitive counterparts. "
03/15/1987 - "Differences also were found in the in vivo metabolism of GSH by L-PAM-sensitive and -resistant murine L1210 leukemia cells. "

07/01/1985 - "Continuous low-dose PTT.119 treatment of MJY-alpha mammary tumor cells for 8 months and exposure of L1210 leukemia to escalating levels of tripeptide for over 100 passages failed to select or induce drug-resistant phenotypes in either cell line. "
01/01/1984 - "The antitumor agent PTT.119 (p-F-Phe-m-bis-(2-chloroethyl)amino-Phe-Met ethoxy HCl) was highly effective against three virulent murine tumor models: the L1210 leukemia, MJY-alpha mammary tumor and B16 melanoma. "
01/01/1990 - "dose at 5-10 mg/kg on day 2 or in two injections of 5-7 mg each on days 2 and 9 to BDf1 mice with peritoneal L1210 leukemia grafts, PTT.119 increased the life spans (ILS) of the population dying of tumor by 94%-313%. "
01/01/1983 - "Exposure of three diverse tumor cell lines, L1210 leukemia, MJY-alpha mammary tumor, and B16 melanoma to 1 to 50 micrograms PTT.119/ml for 15, 30 or 60 minutes significantly reduced cell survivals. "
01/01/1990 - "The therapeutic efficacy of PTT.119, p-F-Phe-m-bis-(2-chloroethyl)amino-L-Phe-Met-ethoxy HCl, was evaluated using the transplantable L1210 leukemia and Ridgway osteogenic sarcoma tumor lines and the spontaneous C3H/StRos mammary tumor and AKR leukemia tumor models. "

11/01/1992 - "In the preclinical study, this compound was active against mouse leukemia L 1210 and inhibited DNA synthesis. "
12/01/1967 - "Quantitative studies concerning the uptake of mouse thymus DNA by L1210 leukemia cells."
03/15/1996 - "As an illustration of its specificity, this method unambiguously distinguished DNA SSBs induced by X-irradiation of mouse leukemia L1210 cells from DNA DSBs occurring in cells undergoing nucleosomal DNA fragmentation and apoptosis. "
02/01/1995 - "The major site of inhibition in L1210 leukemia cells was DNA synthesis after 60 min incubated with the agents at 25, 50 and 100 microM. "
07/01/1990 - "DNA breaks and repair in the mouse leukemia L1210 cells exposed to three different types of interstrand DNA cross-linkers."

09/29/1995 - "This laboratory previously described an L1210 leukemia cell line (MTXrA) selected for resistance to methotrexate by virtue of impaired transport due to a functional defect in the translocation process. "
08/01/1993 - "Highly purified 5-l-methyltetrahydrofolate (m-THF) and 5-l-formyl-THF (f-THF) preparations were compared for rescuing from methotrexate (MTX) toxicity in DBA2 mice transplanted with L1210 leukemia. "
08/01/1993 - "l-5-formyltetrahydrofolate and l-5-methyltetrahydrofolate rescue in L1210 leukemia treated with high methotrexate doses."
07/25/1992 - "Energy-dependent efflux of methotrexate in L1210 leukemia cells. "
01/01/1990 - "Methotrexate cytotoxicity as related to irreversible S phase arrest in mouse L1210 leukemia cells."

01/01/1995 - "Many studies have used mouse leukemia L1210/0 as a reference wild-type cell line, and cisplatin-resistant subclones have been derived from it. "
10/01/1981 - "Studies on the resistance of a murine leukemia L1210 cell line cis-diamminedichloroplatinum (II)."
07/01/2003 - "Biological tests performed using leukemia L1210 cells have shown that toxicity of the title complex is similar to that of cisplatin."
05/01/2000 - "Preliminary ID50 values were 0.88 and 1.26 microM, respectively, in cisplatin-sensitive L1210 leukemia. "
11/01/1999 - "On the other hand, the complex [Pt(NH3)(cpcah)Cl2] exhibited antitumor activity against L1210 leukemia in mice comparable to that of cisplatin, resulting at a dose of 42 mg/kg (administered 3 times) in a T/C (mean survival time) of 280%. "

12/01/1959 - "Behavior of L1210 leukemia after heterologous transplantation in rats."
11/01/1997 - "As shown elsewhere, the amount of drug absorbed is sufficient to provide excellent cytotoxic activity in the L1210 leukemia and in human xenograft models after oral administration. "
06/01/1990 - "Several analogues have shown in vivo tumor growth inhibitory activity in the L1210 leukemia model, with the lead compound 5o exhibiting good antitumor activity against murine solid tumors as well as human tumor xenografts."
06/01/1990 - "Compounds that were active in the P388 screen were evaluated in L1210 leukemia, M5076 carcinoma, and MX-1 mammary xenograft assays in mice."
11/01/1985 - "Thus 82, 73, 45, and 80% of the compounds tested were curative for L1210 leukemia, B16 melanoma, M5076 sarcoma, and the MX-1 mammary xenograft, respectively. "

06/01/2002 - "The mice bearing L1210 leukemia receiving combined chemotherapy lived significantly longer than the animals on single agent regimens. "
01/01/1983 - "Chemotherapy-induced pulmonary toxicity in mice bearing L1210 leukemia."
01/01/1977 - "In the case of L1210 leukemia, the antileukemic effect of CPM was enhanced by subsequent BCG administration where a single cycle of combined treatment was applied; treatment by repeated doses of CPM interspersed with BCG was no more effective than CPM chemotherapy alone. "
11/01/1972 - "The effect of chemotherapy on the growth of leukemia L1210. "
06/01/1970 - "The effect of chemotherapy on the growth characteristics and cellular kinetics of leukemia L1210."

07/01/1989 - "The antitumor activity of 1-beta-D-arabinofuranosylcytosine-5'-alkylphosphates (CnPCAs) against L1210 leukemia in mice after oral administration was demonstrated. "
11/01/1997 - "As shown elsewhere, the amount of drug absorbed is sufficient to provide excellent cytotoxic activity in the L1210 leukemia and in human xenograft models after oral administration. "
01/01/1991 - "Therapeutic efficacy of MST-16 was heavily dependent on the treatment schedule: 9 daily oral administrations and treatment every 4 h on day 1 only were much more effective against s.c.-implanted L1210 leukemia than a single dose or five daily administrations giving the same total dose. "
11/01/1991 - "In an attempt to use this property to advantage in oral administration, 1b and ara-C have been orally coadministered to mice with ip L1210 leukemia. "
03/01/1982 - "Antitumor activity of 15 1-acyloxymethyl derivatives of 5-fluorouracil was examined by both intraperitoneal injection and oral administration in L1210 leukemia system. "

04/01/1993 - "Time-resolved measurements were made of near-infrared emission from 5-(N-hexadecanoyl)amino-eosin-labeled L1210 leukemia cells following pulsed-laser excitation. "
07/01/1997 - "Laser scanning confocal fluorescence microscopic analysis provided a direct evidence of the internalization of non-permeant Lucifer Yellow and a dextran of MW 4400 into leukemia L1210 cells when the cells were vortex-stirred in the presence of a high molecular weight polyacrylic acid, A-119 (MW ca. 9 x 10(6)). "
07/13/1995 - "We compared the efficacy of PDT with aluminium disulphonated phthalocyanine (A1S2Pc) and laser light on the doxorubicin-sensitive murine tumors, B16 melanoma (B16), L1210 leukemia (L1210), P388 lymphoma (P388) and the corresponding doxorubicin-resistant lines (B16/Dx, L1210/Dx and P388/Dx). "

03/15/1970 - "[Preliminary studies of the evaluation of immunodepressive activity in L1210 leukemia allografts in mice]."
07/01/1964 - "STUDIES OF LEUKEMIA L1210 HOMOGRAFT IN SWISS HA-ICR MICE."
05/01/1962 - "Further studies on the homograft response in BALB/c mice with L1210 leukemia and a resistant subline."
08/01/1969 - "Leukemia L 1210 homograft in Swiss mice: immunologic, cellular and chemotherapeutic responses."